35747-58-1

Basic information

• Product Name: 5-Amino-2-chlorobenzonitrile
• Synonyms: 3-CYANO-4-CHLOROANILINE HCL;5-AMINO-2-CHLOROBENZONITRILE;2-CHLORO-5-AMINO BENZONITRILE;4-Chloro-3-cyanoaniline;5-aMino-5-chlorobenzonitrile
• CAS NO: 35747-58-1
• Molecular Formula: C₇H₅ClN₂
• Molecular Weight: 152.58
• Mol File: 35747-58-1.mol

Chemical Properties

• Melting Point: 115.5°C
• Boiling Point: 250.67°C (rough estimate)
• Flash Point: 158.913 °C
• Appearance: /
• Density: 1.9802 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.6100 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.15±0.10(Predicted)
• CAS DataBase Reference: 5-Amino-2-chlorobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2-chlorobenzonitrile(35747-58-1)
• EPA Substance Registry System: 5-Amino-2-chlorobenzonitrile(35747-58-1)

Safety Data

• Hazardous Substances Data: 35747-58-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Amino-2-chlorobenzonitrile serves as a valuable research reagent for organic synthesis. Its distinct functional groups allow it to participate in a wide range of chemical transformations, including nucleophilic substitution, electrophilic substitution, and addition reactions. This versatility makes it a useful building block for the development of new organic compounds and materials.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Amino-2-chlorobenzonitrile is utilized as a key intermediate in the synthesis of various active pharmaceutical ingredients (APIs). Its unique structure can be modified to create novel drug candidates with potential therapeutic applications, contributing to the discovery and development of new medications.
Used in Chemical Research:
5-Amino-2-chlorobenzonitrile is also employed as a research reagent in chemical research. Its reactivity and functional group compatibility make it an ideal candidate for studying reaction mechanisms, exploring new synthetic routes, and investigating the properties of novel compounds. This contributes to the advancement of chemical knowledge and the development of innovative chemical processes.

InChI:InChI=1/C7H5ClN2/c8-7-2-1-6(10)3-5(7)4-9/h1-3H,10H2

Upstream product

• 16588-02-6 4-chloro-3-cyanonitrobenzene 
• 78-93-3 butanone 
• 873-32-5 2-Chlorobenzonitrile 

Downstream Products

• 53312-85-9 acetic acid-(4-chloro-3-cyano-anilide) 
• 134811-61-3 2-chloro-5-trifluoroacetylaminobenzonitrile 
• 134811-50-0 diethyl 4-chloro-3-cyanoanilinomethylenemalonate 
• 99902-86-0 4-(3,4-dichlorophenoxy)-1,3-benzenedicarbonitrile 
• 134811-65-7 2-(2-chloro-5-ethylamino)phenyl-4,5-dimethylthiazole 
• 134811-62-4 2-chloro-5-trifluoroacetylaminothiobenzamide 
• 134811-66-8 2-(2-chloro-5-ethylamino)phenyl-4-phenylthiazole 
• 134811-63-5 2-(2-chloro-5-trifluoroacetylamino)phenyl-4,5-dimethylthiazole 
• 134811-58-8 diethyl 4-chloro-3-thiocarbamoylanilinomethylenemalonate 
• 134811-64-6 2-(2-chloro-5-trifluoroacetylamino)phenyl-4-phenylthiazole 
• 134811-59-9 diethyl 4-chloro-3-(4-methyl-2-thiazolyl)anilinomethylenemalonate 
• 134811-87-3 6-Chloro-1-ethyl-4-oxo-7-(4-phenyl-thiazol-2-yl)-1,4-dihydro-quinoline-3-carboxylic acid 
• 134811-67-9 diethyl N-ethyl-4-chloro-3-(4,5-dimethyl-2-thiazolyl)anilinomethylenemalonate 
• 134811-77-1 6-Chloro-1-ethyl-4-oxo-7-(4-phenyl-thiazol-2-yl)-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 

Relevant articles and documents

Insecticidal aromatic amides

The invention relates to compounds of the general formulae (I) and (II) in which the radicals A1, A2, A3, A4, M1, M2, M3, Q, R1, T, W1 and W2 hav

VEGFR TYROSINE KINASE INHIBITORS

Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

CHEMICAL COMPOUNDS

The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b- and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention

Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof

Progesterone receptor modulators of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, are useful for contrace

Use of progesterone receptor modulators

The use of compounds of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6 and R7, are as defined herein, for contraception, hormone replace

THERAPEUTIC CHROMONE COMPOUNDS

Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Therapeutic chroman compounds

Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.

Therapeutic heterocyclic compounds

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Microwave thermolysis VII: Selective diversity in the reduction using sodium hypophosphite under microwave irradiation

The selective reduction of nitro group into amine using sodium hypophosphite under microwave irradiation is described. The rapid reaction, solvent free conditions and selectivity over common functional groups like CN, OH, COOH, CONH2 and halogens are the distinct features of the procedure.

Process for the preparation of substituted aromatic amino compounds

The invention relates to processes for preparing substituted aromatic amino compounds which contain at least one unsaturated --CN bond or carbonyl group on the aromatic radical or in a side chain, by catalytic hydrogenation of appropriate substituted arom